Motor cortex stimulation for facial chronic neuropathic pain: A review of the literature

Guillermo A. Monsalve

Departamento de Neurocirugía, Clínica Nueva, Bogotá D.C., Bogotá D.C., Colombia

E-mail: *Guillermo A. Monsalve - neurocirugiafuncional@clinicanueva.com

*Corresponding author

Received: 12 August 2012 Accepted: 11 September 2012 Published: 31 October 2012

This article may be cited as: Monsalve GA. Motor cortex stimulation for facial chronic neuropathic pain: A review of the literature. Surg Neurol Int 2012;3:S290-311.

Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2012/3/5/290/103023

Copyright: © 2012 Monsalve GA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Facial chronic neuropathic pain (FCNP) is a disabling clinical entity, its incidence is increasing within the chronic pain population. There is indication for neuromodulation when conservative treatment fails. Motor cortex stimulation (MCS) has emerged as an alternative in the advanced management of these patients. The aim of this work is to review the worldwide literature on MCS for FCNP.

Methods: A PubMed search from 1990 to 2012 was conducted using established MeSH words. A total of 126 relevant articles on MCS focused on chronic pain were selected and analysed. Series of cases were divided in (1) series focused on MCS for FCNP, and (2) MCS series of FCNP mixed with other chronic pain entities.

Results: A total of 118 patients have been trialed for MCS for FCNP, 100 (84.7%) pursued permanent implantation of the system, and 84% of them had good pain control at the end of the study. Male: female ratio was about 1:2 in the whole group of studies; mean age was 58 years (range, 28–83), and mean pain duration was 7 years (range, 0.6–25). Four randomized controlled studies have been reported, all of them not focused on MCS for FCNP. The most common complication was seizure followed by wound infection. Preoperative evaluation, surgical techniques, and final settings varied among the series.

Conclusion: MCS for FNCP is a safe and efficacious treatment option when previous managements have failed; however, there is still lack of strong evidence (larger randomized controlled multicentre studies) that MCS can be offered in a regular basis to FNCP patients.

Key Words: Facial neuropathic pain, facial pain, motor cortex stimulation, neuropathic pain, trigeminal deafferentation pain, trigeminal neuropathic pain

INTRODUCTION

Facial chronic neuropathic pain (FCNP) is a disabling, and devastating condition if left untreated. It is characterized by stabbing, burning, and dysesthetic sensation resistant to treatment, and diminishes quality of life. Pain could be located in any of the branches of the trigeminal nerve (V1, V2, or V3), in any combined area of these branches or in a nondermatomeric area of the face. Under the term of FCNP falls the following...
terms: trigeminal neuralgia, trigeminal neuropathic pain (TNP), trigeminal deafferentation pain (TDP), symptomatic trigeminal neuralgia (STN), postherpetic neuralgia (PHN), and atypical facial pain (AFP). [6,38]

When the pharmacological [8,23,126] and rehabilitation treatment fail, surgery should be considered in an escalating rationale of pain treatment. [20] It should begin with less invasive and the most proven options, evolving to the less proven and finally to more aggressive surgical options. [5,15,47,92,110]

Since the early reports of Tsubokawa et al., electrical stimulation of the motor cortex (Motor Cortex Stimulation (MCS)) has been an option to treat patients with chronic neuropathic drug-resistant pain. [118-120] In the worldwide literature, there is a growing interest on stimulation of the motor cortex for treatment of FCNP [Figure 1]. [90] Initially tried for thalamic pain, it has been tried for many treatment-resistant pain syndromes such as phantom limb pain, [95,101,106] postherpetic neuralgia, brachial plexus avulsion, [57] poststroke pain, [52,46,45,50,31,75,106,111] Wallenberg syndrome, [33,49] complex regional pain syndrome, [27,76,108] pain secondary to multiple sclerosis, [112] spinal cord injury pain, [38,111] and posttraumatic brain injury pain. [107] Recently, MCS has also been tried in other nonpainful conditions. [14]

Meyerson et al. in 1993 reported the first MCS placement aiming facial pain with good pain relief. [72] MCS has become one of the last options to treat this painful condition, before considering deep brain stimulation (DBS) of the sensory thalamus or periventricular gray (PVG) matter, even though DBS outcomes have been controversial. [5,31,65,75,92,109,115] Chronic pain management surgical teams are becoming familiar with MCS, and this therapy is appearing in worldwide reports in the current literature. [12,13,19,25,29,67,73,80,84,90,91,94,105,107,119,122] The author presents an updated literature review on the treatment of FCNP with MCS.

**MATERIALS AND METHODS**

A PubMed search from 1990 to 2012 was conducted, only articles in humans, and in English language were selected for analysis, there was no age limit for the search. The strategy of search was “Motor Cortex Stimulation” used in different combinations search with “neuropathic pain”, “facial pain”, “chronic neuropathic pain”, “chronic neuropathic facial pain”, “atypical facial pain”, “trigeminal neuralgia”, “trigeminal neuropathic pain”, “trigeminal deafferentation pain”. The search yielded 126 relevant selected articles. Editorials, animal studies, repeated reports of series of patients, and comments were considered in some cases for the discussion of this review, as well as articles reporting any form of motor cortex stimulation other than implantable and surgical technique, such as repetitive transcranial motor cortex stimulation (rTMS), direct current motor cortex stimulation, and reports on MCS aimed for other chronic pain condition out of FCNP.

Some of the series included patients who had been reported previously by teams of the same surgical centers. For this reason, selection criteria were: (1) reports of series with two or more cases of FCNP treated with MCS; and (2) nonduplicated series of cases if information was available.

**RESULTS**

Table 1 provides a summary of the reported series of cases focused in MCS for FCNP, and Table 2 shows the MCS series of FNCP mixed with other chronic pains (only the FCNP cases are reported) with a relevant number of cases of FCNP (≥2 patients) in those series; details of the demographics, diagnoses, previous pain treatment, surgery, stimulation parameters, and outcomes are also shown. There was a lack of consistency across studies regarding methods used to report and evaluate the outcome. Some authors do not report pain scores as a point in the Visual Analog Scale (VAS), report the pain score in a range of improvement, such as “excellent”, “good”, “fair”, “poor”, or “failure”. In some cases, however, the definitions of these groups were different across studies. For example, 40% pain relief was considered a good outcome to some authors, while others required a >50% improvement to include patients in this category. [20,94]

Taking this fact into account, outcomes in this review have to be taken with critical judgment. Thus far there are 118 patients treated with MCS for FCNP reported in the worldwide literature [Tables 1 and 2], plus other few single-case reports (referenced in this review but not included in the tables). Male:female ratio was about 1:2 in the whole group of studies; mean age of the patients was 58 years (range, 28–85), and mean pain duration at time of implantation was 7 years (range, 0.6–25). Four randomized controlled studies have been reported, [57,80,104,121] all of them not focused on MCS for FCNP; the others are series of cases, within them...
three are prospective series. One hundred of 118 (84.7%) patients were permanently implanted, and among those 84 (84%) had good pain control at the end of the study. Mean follow-up was 30.7 months (range, 3–120). Only one study reported the number of average programings per year, and only one a neuropsychological evaluation of the patients with Minnesota Multiphasic Personality Inventory (MMPI). The most common complication was seizure followed by wound infection in the whole reviewed group. Seventeen studies report the placement of a 4 contact paddle lead, 1 report used a 5-6-5 paddle lead, 1 study placed an 8 contact paddle lead, and another one placed either a 4 contact or an 8 contact paddle lead, the rest of the studies did not report characteristics of the implanted lead. Seventeen studies placed the lead in the epidural space, and 3 reported placement in the subdural space (including within the central sulcus). Most of the reports used only 1 lead for final placement.

Anesthesia technique varied from local to general and in some cases sedation. Most of the studies used a preoperative imaging technique such as magnetic resonance imaging (MRI) scan, computed tomography (CT) scan, functional magnetic resonance imaging (fMRI) or even stereotactic angiography. Three studies used burr hole approach, 12 craniotomy, and 5 a mixed technique. There was an important concordance in most of the studies to use neurophysiology (somatosensory evoked potentials (SSEPs), and intraoperative cortical monitoring (iCM)) for motor cortex localization. Six studies located the lead perpendicular to the central sulcus, five parallel, one mixed, and one studied oblique.

Initial electrical parameters of stimulation were reported in ranges of amplitude: 1–7.6 volts, pulse width: 45–450 μs, frequency: 30–130 Hz; and final parameters were in amplitude: 1.3–9.5 volts, pulse width: 60–450 μs, frequency: 25–130 Hz. There was higher parameters in the final settings compared with those used at initial programming. Most of the studies set the pain improvement cut-off at ≥50% during the trial period to proceed with permanent implantation of the system, but there were an important number of studies that did not clearly report this value. The pain was evaluated in the majority of studies through the VAS, and a minority of reports also used McGill Pain Questionnaire (MPQ), Verbal Scale (VS), Wisconsin Brief Pain Questionnaire (WBPIQ), Brief Pain Inventory (BPI), and others. Finally eight reports used cycling stimulation, while the others did not, or did not report if cyclic or continuous.

**Motor cortex stimulation series focused in facial chronic neuropathic pain**

Since the first report of MCS to treat FCNP, five more series were reported focusing on this therapy for FCNP. Meyerson et al. pioneered the use of MCS for FCNP, reported 10 patients in which 3 of them had central pain as sequelae of cerebrovascular disease (none responded to stimulation), 2 patients had pain from peripheral nerve injuries, 1 of them did not respond, but the other obtained about 50% pain relief, and the remaining 5 patients with Trigeminal Neuropatic Pain (TNP) experienced pain relief from 60% to 90%, thus reporting 6 permanent implantations of the MCS systems. Ebel et al. in 1996 reported seven cases of TNP treated with MCS, of these seven cases, six cases were permanently implanted due to good to excellent pain control during the trial period and the other with pain relief at the follow-up.

Rainov et al. reported two TNP cases with final implantation and success in the pain relief. Brown et al. and Raslan et al. reported the largest series of final implanted cases, eight case series each, Brown’s series is the only one that is prospective and report a neuropsychological evaluation of the patients.

Of these series of reports focused on MCS for FCNP, 50% of them reported use of cycling stimulation while the rest do not. Esfahani et al. reported as complication brain swelling and tonic-clonic seizure in a case during intraoperative neurophysiological testing and electrode grid implantation, this was treated with mannitol and levetiracetam.

Anderson et al. reported a case of a complex chronic pain in trigeminal and glossopharyngeal territory associated with dysphagia successfully treated with MCS, with significant pain control at 2-years follow-up. Recently, Delavallée et al. reported the first pediatric patient (3 years old) treated with MCS for FCNP secondary to a malignant glioma in the cerebellopontine angle; the patient had pain control at the 12-months follow-up.

**Motor cortex stimulation series of facial chronic neuropathic pain mixed with other chronic pain entities**

Fifteen series of cases are reported thus far, with four controlled randomized studies. Nguyen et al. reported the first mixed series of cases of FCNP with other causes of chronic facial pain, found a 75–100% improvement in the pain in the FCNP group with MCS, they use the neuronavigation technique for lead localization, which led to improved the outcomes. Carroll et al. reported that in none of the two patients with FCNP did the MCS trial work, thus none of the patients had permanent implantation of the system; interestingly, this was the series of cases with older patients. Smith et al. showed that in only one case, out of three, there was long-term pain relief.

Henderson et al. treating two cases of FCNP with loss of pain relief over time showed that with “intense programming” they were able to recapture the benefit, widening the range of initial parameters. Fagundes-Pereyra et al. reported 6 cases of a total of 27 patients with different types of pain, found that in the whole group of patients, 15 (57.7%) the pain was relieved in
Table 1: Description of the series of cases focused in motor cortex stimulation for facial chronic neuropathic pain

| Author(s)          | No. of patients | Type of report | Permanent implantation | Surgery from (year) to (year) | Male: Female ratio | Age at implantation (mean, range) (years) | Previous pain medications and treatment | Neuro-psychological evaluation | Etiology of the pain | Mean pain duration (range) (years) | Fails after permanent implantation | Report of final success | Mean follow-up – months (range) | Average programming sessions/year |
|--------------------|-----------------|----------------|------------------------|-------------------------------|-------------------|------------------------------------------|------------------------------------------|---------------------------------|-----------------------|----------------------------------|-----------------------------|--------------------------|---------------------------------|---------------------------------|
| Meyerson et al.    | 10              | Series of cases | 6                      |                               | 3:7               | 51.2 (44–71)                            | Gasserian ganglion stimulation, DBS, spinal cord stimulation | NM                | NM                                 | 6.3 (2–14)                       | None                     | 6                               | 12.6 (4–28)                     | NR                       |
| Ebel et al.        | 7               | Series of cases | 6                      | 1993–1995                   | 1:6               | 55.4 (37–81)                            | Buprenorphine, baclofen, carbamazepine, tildine, tramadol, metamizol, amitryptiline, local anesthetics, maprotilin, morphone, high cervical cordotomy, parapontine trigeminal rhizotomy, microvascular, compression, retrogasserian injection of glycerol, thermal rhizotomy, stimulation of the ganglion of Gasser, local anesthetics blocks, decompression of the maxillary nerve | NM                | NM                                 | 8 (1–21)                        | None                     | 6                               | 05 to 24                       | NR                       |
| Rainov et al.      | 2               | Series of cases | 2                      |                               | 0:2               | 51.2 (43–60)                            | Carbamazepine, microvascular decompression, thermal lesion of the gasserian ganglion, TENS, phenytoin, phenobarbital | NM                | 2 TNP                              | NM                            | None                     | 2                               | 71 (69–72)                      | NR                       |

(Contd...)
| Author(s) | No. of patients | Type of report | Permanent implantation | Surgery from (year) to (year) | Male: Female ratio | Age at implantation (mean, range) (years) | Previous pain medications and treatment | Neuro-psychological evaluation | Etiology of the pain | Mean pain duration (range) (years) | Fails after permanent implantation | Report of final success | Mean follow-up (range) (months) | Average programming sessions/year |
|-----------|-----------------|----------------|------------------------|-------------------------------|-------------------|------------------------------------------|----------------------------------------|--------------------------------|-------------------|-------------------------------|---------------------------------|-------------------------|-----------------------------|-----------------------------|
| Brown and Pilitisis (2005)[5] | 10 | Prospective, series of cases | 8 | 1999–2002 | 6:4 | 55 (37–73) | Carbamazepine, gabapentin, antidepressants | MMPI | 9 patients: TNP from postherpetic neuralgia, surgical injury, or unknown cause, 1 pain of central origin | 6 (1–12) | None | 8 | 10 (3–24) | NR |
| Esfahani et al.[26] | 3 | Retrospective, case series | 3 | 2003–2009 | 2:1 | 61.3 (41–83) | Baclofen, carbamazepine, clonazepam, duloxetine, gabapentin, pregabalin, tramadol, fentanyl, hydromorphone, hydrocodone/acetaminophen | NM | 1 postherpetic neuralgia, 2 TDP | 9.3 (9–10) | None | 3 | NM | NR |
| Raslan et al.[94] | 11 | Retrospective, case series | 8 | 2008–2011 | 3:8 | 47.3 (31–76) | TNP: 3 dental procedure, 1 facial trauma, 1 surgical trauma of the trigeminal nerve, 1 Wallenbergs syndrome, 1 sinus surgery, 1 idiopathic trigeminal neuropathy TNP: 2 had MVD, 1 had anesthesia dolorosa | NM | NM | 4.5 (1–12) | 3 at 6 months of follow-up | 5 | 33 (6–72) | 2.2 |

(Contd...)
| Complications                  | Surgical lead | Location | No. of leads implanted per patient | Anesthesia during electrode placement | Preoperative imaging | Approach technique | Intraoperative neurophysiology | Neuro-navigation | Lead orientation | Initial stimulation parameters (after implantation) | Pain reduction cutoff during trial | Pain evaluating scales | Final stimulation parameters | Seizures | Stimulation cycling |
|--------------------------------|---------------|----------|-----------------------------------|----------------------------------------|----------------------|--------------------|---------------------|-----------------|-----------------|---------------------------------------------|---------------------------------|------------------|----------------------|----------|-------------------|
| Seizures, skin erosion (2 patients) | 4-CPL         | ED       | 1                                 | L                                      | NR                   | BH/CrT             | SSEPs, iCM          | No              | Not clearly mentioned | Amp: 70-80% to produce muscle twitching, PW: 300 µs, Freq: 50 Hz | 50%                             | VAS               | NR                   | Yes      | Yes               |
| Seizure                        | 4-CPL         | ED       | 1                                 | L                                      | NR                   | CrT/BH (in the neuro-navigation case) | SSEPs              | Yes, only in one case | NR              | Amp: 3.5–8.5 V, PW: 180–350 µs, Freq: 60–130 Hz, bipolar | 50%                             | VAS               | In one case: Amp: 5–6 V, PW: 400 µs, Freq: 100 Hz | Yes (1 case) | Yes               |
| Seizure                        | 4-CPL         | ED       | 1                                 | L                                      | MRI and CT           | CrT                | SSEPs, iCM, EMG     | No              | NR              | Amp: 1–3 V, PW: 90 µs, Freq: 40 Hz                         | 50%                             | VAS               | Amp: 2–8 V, PW: 90–240 ms, Freq: 40 Hz                   | No                   | No                |
| 1 wound infection at 6 months postoperative | 4-CPL         | ED       | 1                                 | G                                      | Stereotactic RMN    | CrT                | SSEPs, iCM, EMG     | Yes             | Parallel         | Amp: 1.6 ± 1.4 V, PW: 93.3 ± 5.8 ms, Freq: 43.3 ± 5.8 Hz | 50%                             | VAS               | Amp: 2–5 V, PW: 120–450 µs, Freq: 30–50Hz                | Yes                  | No                |
| Brain swelling, seizure        | 5-6-5 PL      | SD       | 1                                 | G                                      | 3T fMRI              | CrT                | iCM                | Yes             | Not explicitly mentioned | Amp: 2–5 V, PW: 120–450 µs, Freq: 30–50Hz                | 50%                             | VAS               | Amp: 2–5 V, PW: 120–450 µs, Freq: 30–50Hz                | Yes                  | No                |
| None                           | 4-CPL or 8-CPL| ED       | 1                                 | G                                      | Stereotactic RMN    | CrT                | SSEPs, iCM          | Yes             | Parallel         | Amp: 2–5 V, PW: 120–450 µs, Freq: 30–50Hz                | 50%                             | VAS               | NR                   | No       | No                |

TNP: Trigeminal neuropathic pain, TDP: Trigeminal deafferentation pain, Amp: Amplitude, PW: Pulse width, Freq: Frequency, V: Volts, ms: milliseconds, Hz: Hertz, VAS: Visual analog scale, MPQ: McGill pain questionnaire, IDC: Inventory of drug consumption, MMPI: Minnesota Multiphasic Personality Index, MQS: Medication quantification scale, BPI: Brief Pain Inventory, SIP: Sickness Impact Profile, NM: Not mentioned, NR: Not reported, iCM: Intraoperative Cortical Monitoring, 4-CPL: 4 contact paddle lead, 8-CPL: 8 contact paddle lead, 5-6-5 PL: 5-6-5 paddle lead, BH: Burr Hole, CrT: Craniotomy, ED: Epidural, SD: Subdural, L: Local, G: General
| Author(s)            | No. of patients | Type of report | Permanent implantation | Surgery from (year) to (year) | Male: Female Ratio | Age at implantation (mean, range) (years) | Previous pain medications and treatments | Neuro-psychological evaluation | Etiology of the pain | Mean pain duration (range) (years) | Fails after permanent implantation | Report of final success | Mean follow-up – months (range) | Average programming sessions/year |
|----------------------|-----------------|----------------|------------------------|------------------------------|-------------------|------------------------------------------|------------------------------------------|---------------------------------|------------------|-----------------------------------|-------------------------------|-------------------------|-------------------------------|-------------------------------|
| Nguyen et al.[77]    | 7               | Series of cases| 7                      | 1993–1995                    | 2:5                | 62.3 (43–77)                            | Deep brain stimulation of the thalamus in one case | NM                              | 3 anesthesiology dolorosa, 2 sinus surgery, 1 skull base trauma, 1 surgical trigeminal nerve trauma | 8.4 (5–15)                                      | None                    | 7                            | 28.3 (17–39)                      |                        |
| Nguyen et al.[78]    | 12              | Series of cases| 12                     | 1993–1997                    | Not stated in the facial pain group, general group (18:14) | 62.3 (43–77) | 7 from thermal rhizotomy, 3 from ENT operation, 1 from brainstem lesion, 1 from skull base trauma | Not stated in the facial pain group, general group | NM                              | 7.8 (4–14)                                      | None                    | 9                            | Not stated in the facial pain group, general group: 27.3 (3–50) |                        |
| Carroll et al.[12]   | 2               | Prospective, series of cases | 0                     | 1996–1998                    | 1:1                | 80                                       | NM                                       | NM                              | 1 poststroke (thalamic infarct) with previous stereotactic mesencephalotomy and cingulotomy, 1 with poststroke and trigeminal neuralgia | 8.5 (6–11)                                      | N/A                     | 0                            | N/A                                | N/A                      |
| Smith et al.[104]    | 3               | Prospective, randomized, double-blind, within-patient repeated cross-over study | 3                     | 1996–1998                    | 1:2                | 71.3 (54–80)                            | NM                                       | NM                              | 1 posttraumatic neuralgia, 2 poststroke pain | Not stated in the facial pain group | 2                        | 1                            | 36                             | NR                          |
| Henderson et al.[41] | 2               | Series of cases | 2                      | NM                          | 0:2                | 66 (55–77)                              | Stellate block, morphine pump, neurectomy of the trigeminal nerve | NM                              | 1 atypical facial pain, 1 postherpetic facial pain | 4                                | N/A                     | 2                            | N/A                                | NR                          |

(Contd...)
Table 2: Contd…

| Author(s)          | No. of patients | Type of report | Permanent implantation | Surgery from (year) to (year) | Male: Female Ratio | Age at implantation (mean, range) (years) | Previous pain medications and treatments | Neuro-psychological evaluation | Etiology of the pain | Mean pain duration (range) (years) | Fails after permanent implantation | Report of final success | Mean follow-up – months (range) | Average programming sessions/ year | Fails after permanent implantation | Report of final success | Mean follow-up – months (range) | Average programming sessions/ year |
|--------------------|----------------|----------------|------------------------|-------------------------------|--------------------|------------------------------------------|------------------------------------------|-----------------------------------|----------------------|-----------------------------------|-----------------------------------|-------------------------------|---------------------------------|-------------------------------|-----------------------------------|-------------------------------|---------------------------------|-------------------------------|-------------------------------|
| Pirotte et al.[39] | 6              | Prospective, series of cases | 6                      | Since 1998                   | 2:4                | 60.8 (38–70)                           | NSAID, thermocoagulation, balloon compression, microvascular decompression, carbamazepine, radiation therapy, tricyclic antidepressants, benzodiazepines, deep brain stimulation | NM                               | 4 trigeminal neuropathy, 1 dental avulsion, 1 multiple sclerosis, 1 subcortical stroke group | None                               | 6                              | 26.2 (4–60)                  | NR                               |
| Gharabaghi et al.[36] | 2              | Series of cases | 2                      | NM                           | 2:0                | 65 (61–69)                             | NM                                                     | NM                               | 1 trigeminal anesthesia dolorosa, 1 trigeminal pain | Not stated in the facial pain group | None                           | 2                               | 27 (14–40)                       | NR                               |
| Rasche et al.[95]  | 10             | Retrospective, case series | 5                      | 1994–2006                    | 0:10               | 64.1 (44–82)                           | Ibuprofen, tramadol, gabapentin, amitriptylin, promethazin, paracetamol, phenytoin, buprenorphin | NM                               | 3 dental surgery, 4 trigeminal neuralgia, 3 nerve injury | 6.3                               | None                           | 5                               | 50.4 (12–120)                    | NR                               |
| Cioni et al.[15]   | 8              | Series of cases | 8                      | NM                           | Not stated in the facial pain group | NM                       | NM                                                     | NM                               | 4 posttraumatic, 2 postherpetic, 1 posttrigeminal surgical lesion, 1 multiple sclerosis | NM                               | 7                              | 1                               | NM                               | NR                               |
| Hosomi et al.[46]  | 2              | Retrospective, case series | 2                      | NM                           | 1:1                | 52 (28–76)                             | Pharmacologic therapy, Transcranial magnetic stimulation, nerve blocks | NM                               | 1 pontine infarction, 1 trigeminal pain | 1.95                               | None                           | 2                               | 31.5 (5–58)                      | NR                               |
Table 2: Contd…

| Author(s)          | No. of patients | Type of report          | Permanent implantation | Surgery from (year) to (year) | Male: Female Ratio | Age at implantation (mean, range) (years) | Previous pain medications and treatments                                                                 | Neuro-psychological evaluation | Etiology of the pain | Mean pain duration (range) (years) | Fails after permanent implantation | Report of final success | Mean follow-up – months (range) | Mean programming sessions/year |
|--------------------|-----------------|-------------------------|------------------------|-------------------------------|-------------------|-------------------------------------------|-----------------------------------------------------------------|----------------------------------|------------------------|---------------------------------|----------------------------------|-------------------------------|-------------------------------|----------------------------------|
| Velasco et al.     | 2               | Prospective, randomized double-blind trial | 2                     | NM                            | 1:1               | 37.5 (43–52)                             | “All patients were treated with multiple analgesics drugs, nerve and sympathetic blocks” | NM                              | 1 Thalamic infarct with pain in V2-V3, 1 postherpetic neuralgia with pain in V1 | 3.8 (0.6–7)                      | None                            | 2                             | 12                            | NR                             |
| Nguyen et al.      | 3               | Prospective, double-blinded crossover trial | 3                     | NM                            | 1:2               | 54.3 (31–75)                             | NM                                                                         | 3 trigeminal neuropathy        | 4.6 (3–6)                         | 1                               | 2                               | Not clearly stated for the facial pain group | NR                             |
| Delavallée et al.  | 3               | Series of cases         | 3                     | 2000–2005                     | 2:1               | 62.3 (54–71)                             | Thermocoagulation, MVD, medical treatment                           | NM                              | 3 TNP                              | 18 (9–25)                       | None                            | 3                             | Not clearly stated for the facial pain group | NR                             |
| Lefaucheur et al.  | 7               | Prospective, randomized controlled trial | 6                     | NM                            | 1:6               | 58.8 (30–80)                             | Alprazolam, clomipramine, clonazepam, clorazepam, fentanyl, morphine sulfate, sertraline, tramadol, gabapentin, buprenorphine, levomepromazine, amitriptyline, carbamazepine, venlafaxine, codeine, oxcarbazepine, paracetamol anticonvulsants, antidepressants, antiinflammatory agents, opioid drugs | NM                              | 1 neurofibromatosis type 1, 4 trigeminal neuralgia, 1 herpes zoster ophthalmicus, 1 atypical orofacial pain | 10 (4–20)                        | None                            | 6                             | Not clearly stated for the facial pain group | NR                             |
| Fagundes-Pereyra et al. | 6          | Series of cases         | 6                     | 1994–2002                     | 5:1               | 49.5 (35–67)                             | 2 strokes, 2 brain injury, 1 TNP, 1 multiple sclerosis               | NM                              | 2 strokes, 2 brain injury, 1 TNP, 1 multiple sclerosis | 5.6 (2–10)                      | None                            | 6                             | Not clearly stated for the facial pain group | NR                             |
### Table 2: Contd…

| Complications | Surgical lead | Location | No. of leads implanted per patient | Anesthesia during electrode placement | Preoperative imaging | Approach technique | Intraoperative neuro-physiology | Neuro-navigation | Lead orientation | Initial stimulation parameters (after implantation) | Pain reduction cutoff during trial | Pain evaluating scales | Final stimulation parameters | Seizures | Stimulation cycling |
|---------------|---------------|----------|-----------------------------------|---------------------------------------|---------------------|-------------------|-------------------------|------------------|-----------------|-----------------------------------------------|-----------------------------|---------------------|-----------------------------|----------|------------------|
| Epidural hematoma, transient aphasia and dysesthesia | 4-CPL | ED | 1 | L | fMRI | BH/CrT | SSEPs, iCM | Stereotactic frame | Not clearly mentioned | NR | NR | VAS | Amp: 2.4 V (1.3–4 V), PW: 90 µs (60–180 µs), Freq: 40.8 Hz (25–55 Hz) | No | Yes |
| 1 infection report in the facial pain group | 4-CPL | ED | 1 | L/G | Stereotactic CT scan | BH/CrT | SSEPs | | Yes in some cases, not clearly stated in the facial pain group | NR | NR | VAS, MQS | Amp: 2.1 V (1.3–4) V, PW: 82.5 ms (60–180 ms), Freq: 40 (25–55) Hz | No | Yes |
| N/A | 4-CPL | ED | 1 | G | NR | CrT | iCM | NM | NM | N/A | N/A | Percentage of pain relief, 4-point verbal rating scale, 5-point scale, changes in analgesic consumption | N/A | N/A | N/A |
| Wound infection | 4-CPL | ED | 1 | L/sedation | MRI | CrT | iCM | No | Parallel | NR | 50% | VAS, MPQ | Amp: 2.1 V, PW: 450 µs, Freq: 20 Hz | Not in the facial pain group | NR |

(Contd...)
Table 2: Contd…

| Complications | Surgical lead | Location | No. of leads implanted per patient | Anesthesia during electrode placement | Preoperative imaging | Approach technique | Intraoperative neuro-physiology | Neuro-navigation | Lead orientation | Initial stimulation parameters (after implantation) | Pain reduction cutoff during trial | Pain evaluating scales | Final stimulation parameters | Seizures | Stimulation cycling |
|---------------|---------------|----------|-----------------------------------|---------------------------------------|----------------------|-------------------|-------------------|-----------------|----------------|---------------------------------|-------------------|----------------|------------------------|----------|------------------|
| Seizures.     | 4-CPL         | NM       | 2                                 | N/A                                   | N/A                  | N/A               | N/A               | Parallel         |                | Amp: 5.5–7.6 V, PW: 450 µs, Freq: 110–130 Hz | 50%               | VAS             |                        | Yes      | Yes              |
| Infection, seizure | 4-CPL         | ED       | 1                                 | G                                     | 1.5 T fMRI           | CrT               | SSEPs, iCM         | Yes             | Perpendicular | Monophasic square wave pulses, Freq: 40 Hz, PW: 100 µs, Amp: 1–5 V | NR                | VAS             | NR                     | Yes      | Yes              |
| NR            | 4-CPL         | ED       | 1                                 | L                                     | 1.5 T MRI, 3 T fMRI  | BH                | iCM               | Yes             | Not explicitly mentioned | NR                | Not clearly stated | VAS             | NR       | No               |
| Seizure, wound infection | 4-CPL         | ED       | 1                                 | L /sedation MRI /fMRI                 | BH                   | SSEPs, iCM         | Yes             | Perpendicular | NR             | 50%               | VAS | Amp: 3.5–4.5 V, PW: 210–360 µs, Freq: 50–85 Hz | Yes      | Yes              |
| NR            | Not clearly stated | ED | 1 to 2                            | NM                                   | NR                   | BH/CrT            | NM               | NM              | NR             | NR             | NR             | NR             | NR | NR               |
| Not reported in the facial pain group | 4-CPL         | SD, and within the central sulcus | 1 to 2 | G                                    | MRI                 | CrT               | SSEPs            | None            | Parallel       | NR             | VAS, SF-MPQ | NR | Not in the facial pain group | NR | NR               |

(Contd…)
Table 2: Contd…

| Complications                                      | Surgical lead | Location | No. of leads implanted per patient | Anesthesia during electrode placement | Preoperative imaging | Approach technique | Intraoperative neuro-physiology | Neuro-navigation | Lead orientation | Initial stimulation parameters (after implantation) | Pain reduction cutoff during trial | Pain evaluating scales | Final stimulation parameters | Seizures | Stimulation cycling |
|-----------------------------------------------------|---------------|----------|------------------------------------|----------------------------------------|----------------------|--------------------|------------------------|-----------------|-----------------|-----------------------------------------------|-------------------------------|-------------------------|-------------------------------|-----------|-------------------|
| None                                                | 4-CPL ED      | 1        | G MRI CrT SSEPs, iCM               | None Parallel                         | Amp: 2–3.5 V, PW: 90 µs, Freq: 40 Hz | Not clearly stated | VAS, MPQ | None            | Amp: 2–6.5 V, PW: 90 µs, Freq: 40 Hz | No | Yes |
| None                                                | 4-CPL ED      | 1        | L/G MRI CrT SSEPs, iCM Yes         | Perpendicular                         | Amp: 2 V, PW: 60 µs, Freq: 40 Hz | NR                 | VAS, VS, WBPOQ, MPQ, MQS   | No | NR |
| Wound infection, seizures, arachnoiditis            | 8-CPL SD      | 1        | G NR CrT SSEPs, iCM Yes Oblique    | >40% NR                               | Amp: 1.5–4 V, PW: 210 µs, Freq: 45–80 Hz | Yes | VAS | Yes | Yes |
| NR                                                  | 4-CPL ED      | 1        | G Yes, but not clearly stated CrT | Perpendicular NR                      | Not clearly stated | VAS, BPI, MPQ, SIP, MQS | Amp: 2–3 V, PW: 60–90 µs, Freq: 45–50 Hz | No | Yes |
| Seizures, scar dehiscence, wound infection          | 4-CPL ED      | 1        | L/G Stereotactic angiography BH/CrT SSEPs, iCM Stereotactic frame Perpendicular | Amp: 2–4 V, PW: 45–60 µs, Freq: 45–60 Hz | NR             | VAS, MPQ | Amp: 2–5.3 V, PW: 60–210 µs, Freq: 45–130 Hz | Yes, not clearly stated in the facial pain group | NR |

TNP: Trigeminal neuropathic pain, TDP: Trigeminal deafferentation pain, Amp: Amplitude, PW: Pulse width, Freq: Frequency, V: Volts, ms: milliseconds, Hz: Hertz, VAS: Visual analog scale, VS: Verbal Scale, MPQ: McGill pain questionnaire, SF-MPQ: Short Form of McGill Pain Questionnaire, IDC: Inventory of drug consumption, MMPI: Minnesota Multiphasic Personality Index, MQS: Medication quantification Scale, BPI: Brief Pain Inventory, SIP: Sickness Impact Profile, NM: Not mentioned, NR: Not reported, N/A: Not available, 4-CPL: 4 contact paddle lead, 8-CPL: 8 contact paddle lead, BH: Burr hole, CrT: Craniotomy, ED: Epidural, SD: Subdural, L: local, G: General
50% or more, and no differences were found in relation to pain location (P=0.81).\cite{25}

Lefaucheur et al. reported on a randomized controlled trial using MCS for refractory peripheral pain (FCNP and others) in 2008. Sixteen patients were enrolled. It included a cross-over trial in which the stimulator was switched “on” or “off” for 1 month in random order with double-blind evaluation of the effects. This period was followed by an open phase during which the stimulator was switched “on” in all patients. The mean rate of pain relief on VAS scores of 48% (range, 0–95%).\cite{37}

Lefaucheur et al. reported a design of a new octopolar lead aimed to be used in MCS therapy, the authors implanted this new lead in the epidural space in 6 patients with poststroke pain. One patient had FCNP, this patient had good pain relief at the follow-up.\cite{63}

**DISCUSSION**

The term “facial pain” encompasses a variety of clinical conditions and their presentations could overlap, and the treatment approaches differ based on nature and severity of pain, as well as its distribution, neurological and psychological variables, and medical comorbidities. FCNP is a syndrome of severe, constant facial pain related to disease or injury to the trigeminal nerve or ganglion. Causes of this type of pain can include injury from sinus or dental surgery, skull and/or facial trauma, or intentional destruction for therapeutic reasons (deafferentation) as well as intrinsic pathological conditions in any part of the trigeminal system.\cite{42}

MCS has become one of the last resorts to treat refractory FCNP and has even been considered as part of a facial pain algorithm of treatment after some other invasive procedures.\cite{103} Considering that in chronic pain management a good result means a decrease of at least 50% of the pain in the VAS, the pain relief for FCNP treated with MCS reported in the literature ranges from 45% to 84% including the present review.\cite{12,22,72,78,79,118}

Brown et al. hypothesized that a possible explanation for these particularly excellent results of MCS in FCNP is that the facial somatotopic representation on the motor cortex is large compared with that of other body regions.\cite{41}

When doing a review of a very variable topic, and varied type of reports and measuring scales in terms of outcome, and specifically reviewing MCS for FCNP, only a limited of focused reports are found, the majority of the reports are mixed series of chronic pain patient, where few patients have FCNP. Reports published vary considerably in terms of surgical techniques, origin of the pain syndromes, and the methods to assess clinical outcome, and the lack of large, multicenter, controlled studies focused on MCS for FCNP, make it difficult to compare the results between the studies and to compare MCS with other pain therapies.

The evidence shows that a positive response is achieved in 44–100% of MCS-treated patients and long-term benefits have been achieved in 0–100% of those patients who responded to initial trials of stimulation, and there is evidence that response to stimulation decreases over time in some patients and “intensive programming” is necessary in those cases to recapture the pain relief of the therapy.\cite{41,104}

Fontaine et al. in a critical review of the literature of MCS for chronic neuropathic pain reported that a good response to MCS (pain relief ≥40–50%) was observed in ~55% of patients who underwent surgery and in 45% in patients with follow-up ≥1 year. VAS scores revealed a 57% of pain improvement. A good response was achieved in 68% of the patients with TNP, higher than 54% of the patients with central pain. At follow-up >1 year this percentage was 50% of the patients improved with TNP treated with MCS. Complications were seizures in 12% in the early postoperative period, infection rate was found in 5.7%, hardware related problems in 5.1%.\cite{29}

DaSilva et al. in a structural and functional MRI study of patients with TNP, found changes in cortical thickness of TNP patients were frequently colocalized and correlated with functional allodynic activations, and include both cortical thickening and thinning in sensorimotor regions, and predominantly thinning in emotional regions of the brain. Overall, such patterns of cortical thickness suggest a dynamic functionally driven plasticity of the brain. These structural changes, which correlated with the pain duration, age-at-onset, pain intensity and cortical activity, may be specific targets for evaluating therapeutic interventions.\cite{17}

Lima et al. in a 22-studies meta-analysis showed a weighted responder rate of 72.6% (95% CI, 67.7–77.4) for MCS for chronic pain in comparison of 45.8% (95% CI, 39.2–51.4) of noninvasive motor cortex stimulation studies.\cite{66} According the European Federation of Neurological Societies (EFNS) guidelines on neurostimulation therapy for neuropathic pain there is level C evidence that MCS is useful in 50–60% of patients with central or peripheral facial neuropathic pain.\cite{66} Considering the words of the pioneer of the MCS therapy for FCNP, “it must be remembered that the forms of pain for which MCS can be effective, in at least half of patients, are those for which there is no, or very few other treatment”.\cite{71} Recently, Lefaucheur et al. published the first randomized controlled trial of MCS for treatment of intractable peripheral neuropathic pain, reporting a similar response rate, with 60% of cases showing good or excellent improvement.\cite{57}

A gradual decrease in efficacy with long-term stimulation is not uncommon in neuromodulation procedures for
chronic pain. Some authors have reported a loss of efficacy over time and indicated that intensive reprogramming may help recapture benefits. In average, patients had lost benefits from stimulation 7 months after implantation. Use of two quadripolar electrode arrays instead of one improved the physician’s ability to recapture beneficial stimulation. Henderson et al. reported recovery of pain control after intensive reprogramming after loss of benefit from MCS for neuropathic pain in six patients. However, with this intense reprogramming the chance to have a seizure increases.

Saitoh et al. points out those patients with good preoperative response to ketamine seem to be good candidates for MCS, however, this topic is controversial and deserves further study, as methods to predict a successful outcome from this relatively invasive procedure would be of great clinical significance.

Nutti et al. reported in a non-FCNP series of patients that the intake in analgesic medications in these patients was decreased in 52% of patients and unchanged in 45% of them, complete withdrawal of analgesic medication was obtained in 56% of patients. Neither preoperative motor status, pain characteristics, type or localization of lesions, quantitative sensory testing, somatosensory evoked potential, nor the interval between pain and surgery were found to predict the efficacy of MCS. The level of pain relief, as evaluated in the first month following implantation was a strong predictor of long-term relief (regression analysis, R = 0.744; P < 0.0001).

Postoperative outcomes are better when patients present with only mild to absent motor weakness in the region of pain and when there is pain in the trigeminal region. When motor weakness was present and was moderate to severe, there was therapeutic benefit in only 15% of the patients, and when motor contractions could not be induced, pain relief was achieved in only 9% of patients.

A number of factors have been proposed to account for failures, including poor case selection, flaws in the electrode implantation technique, inadequate neurostimulator programming, loss of efficacy due to plastic changes in the motor cortex organization, excessive deafferentation of the painful territory, among others. However, despite the fact that these factors have been well recognized and described, the manner in which patients continue to be selected and surgically treated, their devices programmed, their outcomes evaluated and reported, and follow-up conducted is extremely heterogeneous.

Velasco et al. emphasized that the most important factor for success of MCS for chronic pain is the correct electrode placement in the cortical representation of pain territory over the motor cortex, and this is better achieved by combining several imaging and electrophysiological techniques. Cycling modes and stimulation parameters are not as critical as electrode correct placement. Patients with severe or complete deafferentation of the painful territory frequently exhibit poor analgesic response and no modification of allodynia and hyperalgesia by MCS. These patients are probably not good candidates for MCS, and a subacute therapeutic trial aids in identifying these individuals.

Mechanism of action

While MCS provides a significant treatment effect to many patients with FCNP, the mechanism underlying its efficacy remains largely unknown. A central analgesic mechanism has been proposed on the basis of comparative positron emission tomography (PET) studies performed before and after MCS. Neuronal activation (hypermetabolism) of cortical and thalamic areas related with sensory input (sensory thalamus), orbitofrontal cortex, mesencephalon/periaqueductal gray (PAG) and pons, posterior insula, areas of emotional interpretation of pain (cingulated cortex, Brodmann area 24, 32, and 10) was induced by MCS and remained after the stimulator was turned off; interestingly, a similar posttherapy effect was also seen with the use of rTMS of the motor cortex. It is hypothesized that the extent of pain alleviation from MCS also correlates with the increase of blood flow in the cingulate gyrus. This suggests that stimulation reduces the suffering experienced by a patient with chronic pain. Ito et al. showed that successful MCS in poststroke pain patients significantly improves glucose use in the thalamus ipsilateral to MCS.

Fonoff et al. reported in two patients with CRPS when studied with fluorodeoxyglucose (FDG) PET scan, an increased activity during MCS in the cingulate cortex, precentral gyri, posterior insula, inferior medial temporal cortex, nuclei acumbens and the mesencephalic region (periaqueductal gray), and a decreased activity in the thalamus bilaterally. These findings suggest that MCS was able to modulate distant brain regions involved in the circuitry of pain. There is also evidence in animals as well as in humans that the MCS elicits a substantial and selective antinociceptive effect mediated through the endogenous opioid system. Pain has an inhibitory influence over the motor cortex, which can interfere with motor learning capacities. Evidence suggests a relationship between chronic pain and motor-cortex reorganization, but it is still unclear whether one causes the other, and also that interventions aimed at normalizing motor-cortex organization can lead to pain relief. Raij et al. showed suppression in the contralateral motor cortex oscillations (~20 Hz) after painful Aδ- and C-fiber stimuli in healthy subjects, supporting the close relationship between the motor cortex and pain control via both fast- and slow-conducting nociceptive pathways.
within the painful area, or the sensory thresholds improved when the MCS switched “on”, were “good responders” to MCS.\textsuperscript{[21]} Fontaine et al. reported a case with neuropathic facial pain due to peripheral nerve injury and after MCS, the tactile and thermal sensory loss improved, although the mechanisms leading to this effect remain unclear, and this observation enhanced the hypothesis that MCS acts through modulation of the sensory processing.\textsuperscript{[28]}

The thickness of the cerebrospinal fluid (CSF) layer between the dura mater and the cortex below the cathode affects the threshold amplitude for motor responses and the therapeutic stimulation amplitude in MCS.\textsuperscript{[69]} Holshheimer et al. reported based in a mathematical model of MCS, that bifocal (bipolar) stimulation gives the largest motor response in the pain region, and the anode of the bipole is the best electrode for pain management.\textsuperscript{[44]} Sharan et al. in an electric field modeling with an extradural 4 contact paddle electrode and showed that the CSF has a large shunting effect on the effectiveness of the stimulus current. The effective stimulus amplitude depends strongly on the thickness of the CSF layer between the dura and cortex, and essentially, the activating function at the depth of the sulci is minimal.\textsuperscript{[102]}

Canavero et al. found in two patients with central pain syndromes, a decrease in blood flow in the parietal lobe, further decreasing after stimulation by nonpainful maneuvers, suggesting a very important role of the sensory cortex in the generation of anomalous pain states,\textsuperscript{[11]} and based on this results the same group placed an epidural parietal (sensory) cortex stimulating electrode for pain with good pain control\textsuperscript{[7]} but this observation needs further study.

Lefaucheur et al. demonstrated in two patients with extradural MCS (EMCS) and implanted epidural cervical electrodes of spinal cord stimulation (SCS) for pain control, that direct and indirect volleys (D- and I-waves) were produced depending on electrode polarity and montage and stimulus intensity. At low-intensity, anodal monopolar EMCS generated D-waves, suggesting direct activation of corticospinal fibers, whereas cathodal EMCS generated I-waves, suggesting transsynaptic activation of corticospinal tract. The bipolar electrode configuration used in chronic EMCS to produce maximal pain relief generated mostly I3-waves. This result suggests that EMCS induces analgesia by activating top-down controls originating from intracortical horizontal fibers or interneurons but not by stimulating directly the pyramidal tract. The descending volleys elicited by bipolar EMCS are close to those elicited by transcranial magnetic stimulation (TMS) using a coil with posteroanterior orientation. Different pathways are activated by EMCS according to stimulus intensity and electrode montage and polarity, which should be taken into account when programming EMCS for pain treatment.\textsuperscript{[62]}

**Preoperative investigations**

Most of the studies on MCS for chronic pain reported the characterization of the pain with the VAS and MPQ, and few studies included Verbal Rating Scale (VRS), BPI, Sickness Impact Profile (SIP), and Medication Quantification Scale (MQS). WBPQ [Tables 1 and 2].\textsuperscript{[5,25,57,63,78,80,104]} These scales are applied in the preoperative, during the trial, as well as in the postoperative period and follow-ups. In some studies the pain outcome was also reported according to a pain relief scale, similar to this one, but there is some variation between the reports in the ranges of percentages;\textsuperscript{[17,111]}

- **Excellent** (pain reduction from 80% to 100%)
- **Good** (pain reduction from 60% to 79%)
- **Fair** (pain reduction from 40% to 59%)
- **Poor** (pain reduction less than 40%)

Predicting which patients will likely benefit from stimulation is a major clinical problem. Barbiturate sensitivity and opioid insensitivity have been suggested as possible predictors of response.\textsuperscript{[7,120,123]} TMS may be another useful predictor of response.\textsuperscript{[55,56,61,64,87]} Results of such preoperative testing, however, are no guarantee of a successful outcome, as not all patients who respond to propofol respond to MCS and, equally, morphine-insensitive patients have been shown to respond to stimulation.\textsuperscript{[7,104]}

Appropriate pain psychological evaluation and realistic expectations of pain reduction are important preoperative considerations as well. Standardized questionnaires that have been validated for patients with chronic pain may contribute to outcomes measurement. All patients should be evaluated by a pain psychologist before surgery, given the significant psychological burden of pain and the possible contribution of psychological comorbidities to suffering. Screening that reveals significant psychological/psychiatric comorbidities does not preclude intervention, but must be weighted by the relevant health care teams. Patients must be appropriately educated about the procedure, and realistic expectations should be verified.\textsuperscript{[109]}

In patients with epilepsy that have undergone an anterior temporal lobectomy, a number of postoperative complications have been identified in several domains: psychological, behavioral, affective, and social. This postoperative psychological adjustment was first described as the “Burden of Normality” (BoN), and then described as a syndrome.\textsuperscript{[79]} The BoN syndrome is a described phenomenon of postoperative adjustment, and could be applied to chronic pain patient who undergo neuromodulation surgery (for instance, MCS) and who have difficulty coping with the expectations associated with becoming “normal”. The pain psychological team
should be managing and assessing all these situations from the preoperative period to the surgical follow-up. It should be emphasized that psychological and psychiatric evaluations are not routinely reported in the literature review of MCS for FCNP.

Montes et al. demonstrated that MCS may interfere with relatively simple cognitive processes such as that underlying target detection, and that the risk of abnormal cognitive effects related to cortical stimulation may increase with age. MCS surgery appears on the whole remarkably safe, complementary neuropsychological studies in this category of patients are advised, as well as caution to possible adverse cognitive effects when using MCS in the elderly, notably in the presence of preexistent cerebral lesions.

**Surgical technique**

Surgical techniques vary considerably among centers, there is no consensus in many of the issues related to surgery; for instance, the need to trial the MCS, burr hole vs craniotomy, epidural vs subdural electrode placement, time and place (regular floor, outpatient clinic, epilepsy monitoring unit) of the initial programming. There is also questioning about the optimal target area of the stimulation, most of the authors aim the motor cortex, some others place the electrodes in the motor and sensory strips, and there is one report aiming specifically the sensory strip for pain control with good results. Hosomi et al. studied the central sulcus electrode placement and found that during the trial this location was more effective than that of the precentral gyrus, but in the long-term did not significantly improve the outcome. Following the author presents the most usual way to perform MCS.

**Stage I procedure**

In this description, stage I refers to the electrode placement over the motor cortex. There are several proper ways to perform this surgical stage. Antibiotics are administered 30 minutes before incision. Under general anesthesia without muscle relaxant the patient is pinned in the 3-fixation point head holder and after proper cushioning of the bonny parts, the head is rotated to the contrary side of the craniotomy. External landmarks are taken to identify the central sulcus, and also with the aid of fMRI and neuronavigation confirmation, the face and hand area in the precentral gyrus is identified. A small round craniotomy is done (5 × 5 cm) over the target area and the dura carefully coagulated. Epidural neurophysiological testing and confirmation (SSEPs, motor evoked potentials (MEPs), and/or Electromyography (EMG)) of the painful area is performed, central sulcus is localized, two 4 contact paddle lead are perpendicularly placed over the motor and sensory cortex of the painful area, and stitched to the dura mater in several anchoring points. There is also a thought to cover with the stimulation the neighboring area of the pain, for a better pain control and to optimize the programming of the stimulator. The bone flap is relocated and closure is performed.

Saitoh et al. reported a case in which a 4 contact paddle electrode was placed within the central sulcus for pain control, this patient had a pain secondary to spinal cord injury and had an excellent outcome. Insertion of the electrode arrays was originally proposed through burr holes, a trend exists toward performing craniotomies over the sensory cortex. This allows for better electrophysiological (SSEPs and electrical cortical mapping (ECM)) assessment of the motor cortex, which can be performed using electrode grids instead of the electrode itself. The grids cover a greater cortical surface and help refine the location and orientation of the central sulcus, and the generous exposure is also advantageous for securely anchoring the electrode array(s) in position by anchoring sutures. Although some patients could complain of a more painful wound due to the extension of the surgical approach.

Delavallée et al. studied eight patients with chronic neuropathic pain, and subdural plate electrode placement, found that all of the patients with trigeminal neuropathy had excellent and satisfactory outcome at the last follow-up, of the whole group three patients had seizures related to an abrupt increase in stimulation intensity, and two patients had hardware infections that required system replacement.

**Intraoperative monitoring**

SSEPs are used intraoperative for localization of the central sulcus and precentral cortex. The N20-P20 phase reversal is used to identify the central sulcus and to guide the implantation of the permanent electrodes. A grid of electrodes allows for localization of the central sulcus at more than one point, determining its course within the craniotomy. iCM is routinely used intraoperative and can be accomplished with the implantable electrodes or a monitoring grid. The electrode contact that produces motor contraction at the lower thresholds in the topography of pain should be identified. The surgical and anesthesia teams should be watching carefully for the occurrence of contractions and be prepared to manage intraoperative seizures. In patients without corticospinal injuries, iCM is thought to be the “gold standard” for localization, and even if cortical reorganization occurred as consequence of neuronal plasticity.

Yamamoto et al. described in two patients the D-wave of the MEP as an intraoperative indicator for the placement of stimulating electrodes over the motor cortex for pain relief, the percentage VAS reduction was significantly correlated with the D-wave amplitude, indicating that D-wave recording provides and intraoperative guide.
for placing the stimulating electrode at the optimum position on the motor cortex.\cite{124}

Holsheimer et al. reported that monopolar stimulation should be applied in intraoperative neurophysiological testing because, contrary to bipolar stimulation, the corresponding MEPs are unambiguously related to a single stimulating electrode and their amplitude is not affected by the anode–cathode distance. The anode providing the largest MEPs intraoperatively should be selected as the chronic stimulation.\cite{125}

Therefore, direct cortical stimulation (DCS) is the gold-standard technique for motor mapping during craniotomy, and preoperative noninvasive motor mapping is becoming increasingly accurate. Two such noninvasive modalities are navigated TMS and magnetoencephalography (MEG) imaging. Taraòre et al. found that maps of the motor system generated with TMS correlate well with those generated by both MEG imaging and DCS. Negative TMS mapping also correlates with negative DCS mapping; hence navigated TMS is an accurate modality for noninvasive generating preoperative motor maps\cite{114} and this can be a technique to explore for MCS surgery.

Velasco et al. reported that electrophysiological confirmation of the limits between motor and sensory cortices by studying phase-reversal polarity of N20 and P20 components is not always possible, and a more reliable method to determine the transition between somatosensory cortex and motor cortex seems to be corticocortical potential induced by stimulation of different pairs of grid contacts.\cite{122}

Lefaucheur et al. reviewed the literature on intraoperative neurophysiologic mapping of the central cortical region for epidural electrode placement in the treatment of neuropathic pain by MCS, and found 41 reports addressing this theme, with different author’s preference and methods. Lefaucheur et al. recommend basing the localization of the electrode(s) based on MEP recordings in response to monopolar (anodal) stimulation of the cortical region corresponding to the painful area, and MEP mapping cannot be used in patients with total or severe motor deficit, and recommend in this case using fMRI-guided navigation for electrode placement. fMRI has good concordance between contours with SEPs and MEPs.\cite{56}

**Functional MRI scan and neuronavigation**

A critical step in MCS treatment for FCNP is the localization of the somatotopic face region on the precentral gyrus. Recent imaging methods have introduced three-dimensional (3-D) MRI scan reconstruction that uses blood oxygen level-dependent (BOLD) contrast can also be helpful in determining the orientation of the precentral gyrus along the surface of the cortical convexity, specifically the face and hand area.\cite{68}

In a series of reports with increasing number of patients, Pirotte et al. reported 21 patients with different types of neuropathic pain who underwent frameless neuronavigation MCS, all patients had a preoperative fMRI and had iCM with SSEP and motor cortex stimulodetection. Concordance between contours of fMRI activation area and iCM in precentral gyrus (mean distance, 3.8 mm) was found in 95% of the patients. The authors recommend combining both techniques in functional neurosurgical procedures because it can improve the quality of the operative targeting of selective motor cortex areas.\cite{184,186} Gharabaghi et al. operated six patients with the combination of 3-D functional neuronavigation, intraoperative electrical stimulation, and continuous motor output in awake patients and reported that this combined imaging and stimulation approach for electrode positioning offers a safe and minimal invasive strategy for the treatment of chronic pain.\cite{39}

There is also a very useful tool for MCS surgery such as the neuronavigation based on CT or MRI scan. This planning technique was pioneered by Nguyen et al. and the anatomical reference points can clearly be seen on oblique curved scans reconstructions. On these reconstructions, central, lateral, the interhemispheric, superior, and inferior frontal sulci can be clearly identified. The face area in the motor cortex is found 3 cm above the lateral sulcus (Sylvian) and does not exceed the inferior frontal sulcus. The target can thus be easily located and verified in real time on the CT or MRI images by using the pointer or the laser beam of the navigation system.\cite{9,79} Tirakotai et al. reported 5 patients with central pain operated with a minimally invasive technique with the aid frameless neuronavigation and vacuum headrest. All patients obtained postoperative pain relief, no surgical complication occurred, and the postoperative course was uneventful in all patients.\cite{116} Mogilner et al. in a study of 5 patients with chronic pain conditions, and reported that integration of functional and anatomical imaging data allows for precise and efficient surgical planning and may reduce the time necessary for intraoperative physiological verification.\cite{71}

In clinical settings where technology is not available, is expensive, or is not affordable, Velasco et al. recommends a good MRI imaging technique and a reliable iCM.\cite{121}

**Trial period**

This trial period is necessary to assess the effects of the MCS therapy in terms of pain control and side effects; however, there is still a chance to have a placebo effect. Typically the trial lasts 7 days (range, 5–10 days) and in some countries by law the trialing period has to last 30 days.\cite{185} The longer the trial period the higher risk of infection. Others authors do not perform a trial, directly implant the permanent system since the permanent electrode placement.\cite{122} In author’s experience in neuromodulation for chronic pain, during the trial patient should fill in a pain record (time of the day, stimulator...
on or off, settings (stimulation group or program), and day activity, VAS and patient’s comments) to objectivize the pain control with the MCS therapy and support the permanent implantation of the system.

**Stage II procedure**

This stage refers to the implantable pulse generator (IPG) placement. Stage II surgery is always performed under general anesthesia, with a shoulder roll elevating the shoulders and the head slightly rotated to the contrary side of the IPG implantation. Antibiotics are administered 30 minutes before incision. Typically for MCS therapy, the IPG is implanted in the subclavian region; therefore, a subcutaneous pocket is done, the implantation depth depends on the type of generator (nonrechargeable vs rechargeable), and the amount of fat tissue in the patient chest region. For a nonrechargeable IPG or a lean patient, the IPG can be located in the pectoral subfascial layer, and if it is a rechargeable IPG this should be located in a more superficial layer. It is also advisable to follow the recommendations of the manufacturer.

**Surgery closure**

The craniotomy flap site is usually fixed with titanium miniplates to the skull, and the test cable is exteriorized through the scalp in a different wound (counter-opening). After generous saline irrigation, scalp wound is closed in multiple layers, antibacterial absorbable suture 1 or 0 for the galea and deep subcutaneous tissue, antibacterial absorbable suture 3-0 for superficial subcutaneous tissue and subcuticular, and scalp with staples or antibacterial absorbable monofilament 3-0 for intradermal closure, and at the end skin sealant. The external cable is fixed to the scalp with monofilament nonabsorbable suture 2-0.

As the closing of the scalp, chest pocket is closed in multiple layers, taking care of not puncturing the hardware extensions with the needles. Author preference is to close the skin with antibacterial absorbable monofilament suture 3-0, and to apply skin sealant. This manner to close the skin avoids a likely painful stitch removal and diminishes the risk of wound infection.

**Complications**

Although in many studies no adverse events with MCS have been reported,[8,10,10,11] complications of MCS therapy are around 20% of patients experiencing one or more complications, in general of benign nature, but are reported such as battery failure, seizures (in the early or late postoperative period)[91], wound infections (2.2%), wound dehiscence, pain induced by stimulation, epidural or subdural hematoma, gradual diminution of pain relief benefit over a period of time,[10] hardware malfunction.[10] Seizures occasionally occurred during the motor mapping, but chronic seizures have been rarely reported at optimum electrical settings [Table 3].[15,104] Death is an extremely rare complication in MCS therapy.[1,42] Patients and their families should be clearly informed of the potential complications, and the need to look for prompt medical assistance if one or more complications present.

Velasco et al. reported a case of development of epidural fibrosis that interfered with the MCS, which was suspected by means of the increase in electrodes impedance (>2000 Ω) and the loss of effect to evoke cortico-cortical potentials by setting the IPG stimulation at 6–10 Hz, 450 μs, and up to 10.5 V, and this required a surgical removal or the fibrosis. In addition, the same group also reports a migration of the distal part of the electrode outside the area it was originally placed, this was corrected with another surgery.[122]

There are some unusual and very interesting effects related to the MCS, Tomasino et al. reported that the task involving motor imagery were slowed down by cortical stimulation, whereas those involving visual imagery were not. When the patient performed the motor-imagery task, the interference effect on response times disappeared if the stimulator was switched off, hence suggesting that the motor cortex is also involved in higher cognitive functions.[117] Canavero et al. reported a painful supernumerary arm following MCS for central poststroke pain [Table 2],[10] as well as other bizarre phenomena such as: a very unpleasant pain in the

---

**Table 3: Reported side effects and complications with MCS therapy**

| Procedure-related complication |
|-------------------------------|
| Bleeding                       |
| • Epidural hematoma            |
| • Subdural hematoma            |
| • Large cerebral hematomas     |
| Infection                      |
| Postinfection arachnoiditis    |
| Wound dehiscence              |
| Transient neurological deficits|
| Breakage and/or malfunction of the hardware |
| Epidural fibrosis             |

| Stimulation-related complication |
|----------------------------------|
| Seizures                        |
| Painful stimulation of the dura mater |
| Dysesthesia                     |
| Dysarthria                      |
| Fatigue                         |

| Unusual events |
|----------------|
| Impairment in a motor imagery task |
| Development of a painful supernumerary phantom arm |
| Cognitive function alteration |
| Unpleasant pain in the same area of the original pain |
| Analgesia via ipsilateral MCS |
| Bilateral analgesia (or sensory effects) from unilateral MCS |

---

S307
same area of the original pain, analgesia via ipsilateral stimulation, and bilateral analgesia (or sensory effects) from unilateral MCS.\textsuperscript{[9]}

**Permanent stimulation parameters**

Stimulation parameters used for MCS varied considerably not only across studies, but also among patients treated in the same center. The most commonly used settings were 2–3 V (range 0.5–9.5 V), 25–50 Hz (range 15–130 Hz), and 200 μs (range 60–450 μs). It was not possible to established a correlation between stimulation parameters and outcome because individual stings were not reported in several of the articles, stimulation parameters were not systematically studied in all studies, and stimulation settings in nonresponders were rarely reported.\textsuperscript{[20]} For electrodes placed in the subdural space the stimulation parameters are usually less in amplitude, but similar in the pulse width and frequency.\textsuperscript{[18]} Because many investigators have noted that MCS frequently produces a period of poststimulus pain relief that ranges from minutes to hours, many neurosurgeons try a cycling mode of MCS, with 10 minutes to 3 hours on stimulation followed by 15 minutes to 6 hours off stimulation.\textsuperscript{[42]} Once the pain is relieved in the painful region, with no side effects related to the stimulation, electrode polarity and other parameters are adjusted. The optimal stimulation parameters vary widely from patient to patient, and testing requires time and effort to find the settings that provide the most pain relief with the minimum energy use.\textsuperscript{[3,102]} Chronic stimulation was usually conducted in a bipolar configuration.\textsuperscript{[5,12,72,78,81,86,93,118]}

**Cost-effectiveness of motor cortex stimulation**

MCS has crossed 21 years now in the chronic pain management armamentarium, and there is only one report addressing the cost-effectiveness of the therapy. Zaghi et al. studied the cost-effectiveness of the MCS and showed that comparing MCS vs rTMS, and found that at 1 year, rTMS was the most cost-effective approach, but MCS was the most cost-effective modality for neuromodulation of chronic pain at 5-year treatment consideration.\textsuperscript{[125]}

**Key questions and topics**

The functional neurosurgeon facing the patient with FCNP, and considering MCS for treatment should respond these questions before considering and offering MCS as a treatment option:

- Have all the conventional treatments been tried in this case?
- Do I know perfectly this patient and his/her family situation?
- Is there something else that I could offer to this patient before neuromodulation?

There are a number of very interesting points that thus far have not been resolved, or more work needs to be done on them:

- More models of electrodes specifically thought for MCS are needed, besides of the new lead design reported and studied by Lefaucheur et al.\textsuperscript{[65]}
- What is the best electrode placement, epidural or subdural?
- Does the surgeon need to take into account the distance between the dura and the cortex surface, to make a decision on whether place the electrode epidural or subdural?
- What is the best number of electrodes to treat the patients with FCNP?
- Should we change the name of motor cortex stimulation, for sensory cortex stimulation, or sensorimotor cortex stimulation, or simply cortex stimulation?
- What is the best electrode orientation to the central sulcus, parallel or transversal?
- Does the neurosurgeon need to stimulate also the neighbor area to assure a better pain control?
- Is there a pharmacological trial useful before indicating MCS for FCNP?
- Does the rTMS have a role in the preoperative assessment of the patients who undergo MCS for FCNP?

**CONCLUSION**

MCS is a useful and important tool for treating FCNP patients, is a nondestructive, adjustable, and reversible therapeutic technique that is efficient for treating patients presenting FCNP, which are refractory to other types of treatment, even though its mechanisms of action are still not well established.\textsuperscript{[25]} To the light of the current knowledge and the evidence in favor, MCS is a safe and efficacious therapy to include in the range of therapeutic options and to consider in patients with FCNP; however, large prospective randomized, multicenter clinical trials focusing on MCS for FCNP, and with longer follow-ups are needed.

In order to make more comparable the reported studies, more data are necessary to be taken into account (a clear mention of type of study, if patients had psychiatric, psychological and/or neuropsychological evaluations, initial parameters of stimulation, cycling of the stimulation, and other information). There are still some unresolved controversies on the topic, such as electrode placement (epidural vs subdural, perpendicular vs parallel to the central sulcus), number of electrodes, and number of contacts in the electrode, what is the best number of days to trial these patients and several other issues that need to be properly addressed in the next MCS reports.
Moreover, it is therefore important to mention that this procedure be performed by an experienced surgical team (including a functional neurosurgeon with experience in the field of pain), in institutions with the proper technology and expertise in order to minimize surgical risks and deal with complications in a prompt manner.

REFERENCES

1. Ali M, Saitoh Y, Oshino S, Hosomi K, Kishima H, Morris S, et al. Differential efficacy of electric motor cortex stimulation and lesioning of the dorsal root entry zone for continuous vs paroxysmal pain after brachial avulsion. Neurosurgery 2011;68:1252-7; discussion 1257-8.

2. Anderson WS, Kiyofuji S, Conway JE, Busch C, North RB, Garonzik IM. Dysphagia and neuropathic facial pain treated with motor cortex stimulation: Case report. Neurosurgery 2009;65:E626 ; discussion E626.

3. Brown JA. Motor cortex stimulation. Neurosurg Focus 2001;11:E5.

4. Brown JA, Barbaro NM. Motor cortex stimulation for central and neuropathic pain: Current status. Pain 2003;104:431-5.

5. Brown JA, Pilitsis JG. Motor cortex stimulation and neuropathic pain: A prospective study of 10 patients and observations of enhanced sensory and motor function during stimulation. Neurosurgery 2005;56:290-7; discussion 290-7.

6. Burchiel KJ. A new classification for facial pain. Neurosurgery 2003;53:1164-6; discussion 1166-7.

7. Canavero S, Bonicalzi V. Cortical stimulation for central pain. J Neurosurg 1995;83:1117.

8. Canavero S, Bonicalzi V. Drug therapy of trigeminal neuralgia. Expert Rev Neurother 2006;6:429-40.

9. Canavero S, Bonicalzi V. Extracaudal cortical stimulation for central pain. Acta Neurochir Suppl 2007;97(PT 2):27-36.

10. Canavero S, Bonicalzi V, Castellano G, Perezzo P, Massa-Micon B. Painful supernumerary Phantom arm following motor cortex stimulation for central poststroke pain. J Neurosurg 1999;91:121-3.

11. Canavero S, Pagini CA, Castellano G, Bonicalzi V, Belli M, Duca S, et al. The role of cortex in central pain syndromes: Preliminary results of a long-term technetium-99 hexamethylpropyleneamineoxime single photon emission computed tomography study. Neurosurgery 1993;33:185-9; discussion 190-1.

12. Carroll D, Joint C, Maarrawi J, Shligman D, Stein J, Aziz TZ. Motor cortex stimulation for chronic neuropathic pain: A preliminary study of 10 cases. Pain 2000;84:431-7.

13. Cioni B, Meglio M. Motor cortex stimulation for chronic non-malignant pain: Current state and future prospects. Acta Neurochir Suppl 1997;79:45-53.

14. Cioni B, Meglio M, Perrotti V, De Bonis P, Montano N. Neurophysiological aspects of Chronic motor cortex stimulation. Neurophysiol Clin 2007;37:441-7.

15. Cheshire WP. Trigeminal neuralgia: For one nerve a multitude of treatments. Pain 2000;84:431-7.

16. Ebel H, Rust D, Troinnier V, Böker D, Kunze S. Chronic precentral stimulation in trigeminal neuropathic pain. Acta Neurochir (Wien) 1996;138:1300-6.

17. Eisenberg E, River Y, Shifrin A, Krikov N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007;67:1265-89.

18. Esfahani DR, Pisanly MT, Dafer RM, Anderson ME. Motor cortex stimulation: Functional magnetic resonance imaging-localized treatment for three sources of intractable pain. J Neurosurg 2011;114:189-95.

19. Fagundes-Pereyra WJ, Teixeira MJ, Reyns N, Touzet G, Dantas S, Laureau E, et al. Motor cortex electric stimulation for the treatment of neuropathic pain. Arq Neuropsiquiatr 2010;68:923-9.

20. Fontono ET, Dale CS, Pagano RL, Paccolla CC, Ballester G, Teixeira MJ, et al. Antinoception induced by epidural motor cortex stimulation in naive conscious rats is mediated by the opioid system. Behav Brain Res 2009;196:63-70.

21. Fontono ET, Hamani C, Ciampi de Andrade D, Yong LT, Marcolini MA, Jacobson Teixeira M. Pain relief and functional recovery in patients with complex regional pain syndrome after motor cortex stimulation. Stereotact Funct Neurosurg 2011;89:167-72.

22. Fontaine D, Bruneto JL, El Fakir H, Paquis P, Lanteri-Minet M. Short-term restoration of facial sensory loss by motor cortex stimulation in peripheral post-traumatic neuropathic pain. J Headache Pain 2009;10:203-6.

23. Fontaine D, Hamani C, Lozano A. Efficacy and safety of motor cortex stimulation for Chronic neuropathic pain: Critical review of the literature. J Neurosurg 2009;110:251-6.

24. Forssell H, Tenovuo O, Pääkkö P, Santavuori P. Differences and similarities between atypical facial pain and trigeminal neuropathic pain. Neurology 2007;69:1451-9.

25. Franzini A, Cordella R, Nazzini V, Broggi G. Long-term Chronic stimulation of internal capsule in poststroke pain and Spasticity. Stereotact Funct Neurosurg 2008;86:179-83.

26. Fukaya C, Katayama Y, Yamamoto T, Kobayashi K, Kiasai M, Oshima H. Motor cortex stimulation in patients with post-stroke pain: Conscious somatosensory response and pain control. Neurol Res 2003;25:153-6.

27. García-Larrea L, Maarrawi J, Peyron R, Costes N, Mertens P, Magnin M, et al. On the relation between sensory deafferentation, pain and thalamic activity in Wallenberg’s syndrome: A PET-scan study before and after motor cortex stimulation. Eur J Pain 2006;10:677-88.

28. García-Larrea L, Peyron R. Motor cortex stimulation for neuropathic pain: From phenomenology to mechanisms. NeuroImage 2007;37(Suppl):S71-9.

29. García-Larrea L, Peyron R, Mertens P, Grégoire MC, Lavenne F, Bonnefoi F, et al. Positron emission tomography during motor cortex stimulation for pain control. Stereotact Funct Neurosurg 1997;68:141-8.

30. García-Larrea L, Peyron R, Mertens P, Grégoire MC, Lavenne F, Le Bars D, et al. Electrical stimulation of motor cortex for pain control: A combined PET-scan and electrophysiological study. Pain 1999;83:259-73.

31. García-Larrea L, Peyron R, Mertens P, Laurent B, Mauguière F, Sindou M. Functional imaging and neurophysiological assessment of spinal and brain thermoeutropic modulation in humans. Arch Med Res 2000;31:248-57.

32. Gharsabghi A, Hellwig D, Rossahl SK, Shahidi R, Schrader C, Freund HJ, et al. Volumetric image guidance for motor cortex stimulation: Integration of three-dimensional cortical anatomy and functional imaging. Neurosurgery 2005;57(Suppl 1):114-20; discussion 114-20.

33. Gilbert F. The burden of normality: From ‘chronically ill’ to ‘symptom free’. New ethical challenges for deep brain stimulation postoperative treatment. J Med Ethics 2012;38:408-12.

34. Graff-Radford SB. Facial pain. Neurologist 2009;15:171-7.

35. Henderson JM, Boongird A, Rosenow JM, LaPresto E, Rezai AR. Recovery of pain control by intensive reprogramming after loss of benefit from motor cortex stimulation for neuropathic pain. Stereotact Funct Neurosurg 2004;82:207-13.

36. Henderson JM, Lad SP. Motor cortex stimulation and neuropathic facial pain. Neurosurg Focus 2006;21:E6.

37. Holsheimer J, Lefaucheur JP. Buitenweg JR, Goujon C, Nibe N, Nguyen JP. The role of intra-operative motor evoked potentials in the optimization of chronic cortical stimulation for the treatment of neuropathic pain. Clin Neurophysiol 2007;118:2287-96.

38. Holsheimer J, Nguyen JP, Lefaucheur JP, Manola L. Caudal, and/or bifocal stimulation of the motor cortex in the management of chronic pain!. Acta Neurochir Suppl 2007;97(2):57-66.

39. Hosomi K, Saitoh Y, Kishima H, Oshino S, Hirata M, Tani N, et al. Electrical
stimulation of primary motor cortex within the central sulcus for intractable neuropathic pain. Clin Neurophysiol 2008;119:993-1001.

46. Ito M, Kuroda S, Shiga T, Tamaki N, Iwasaki Y. Motor cortex stimulation improves local cerebral glucose metabolism in the ipsilateral thalamus in patients with poststroke pain: Case report. Neurosurgery 2011;69:E62-9.

47. Johnson MD, Burchiel KJ. Peripheral stimulation for treatment of trigeminal postherpetic neuralgia and trigeminal posttraumatic neuropathic pain: A pilot study. Neurosurgery 2004;55:135-41; discussion 141-2.

48. Katayama Y, Fukaya C, Yamamoto T. Poststroke pain control by chronic motor cortex stimulation: Neurological characteristics predicting a favorable response. J Neurol 1998;285:585-91.

49. Katayama Y, Tsubokawa T, Yamamoto T. Chronic motor cortex stimulation for central deafferentation pain: Experience with bulbar pain secondary to Wallenberg syndrome. Stereotact Funct Neurosurg 1994;62:295-9.

50. Katayama Y, Yamamoto T, Kobayashi K, Kasai M, Oshima H, Fukaya C. Motor cortex stimulation for post-stroke pain: Comparison of Spinal cord and thalamic stimulation. Stereotact Funct Neurosurg 2001;77:183-6.

51. Katayama Y, Yamamoto T, Kobayashi K, Oshima H, Fukaya C. Deep brain and motor cortex stimulation for post-stroke Movement disorders and post-stroke pain. Acta Neurochir Suppl 2003;87:121-3.

52. Khedr EM, Kotb H, Kamel NF, Ahmed MA, Sadek R, Rothwell JC. Long-lasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain. J Neurol Neurosurg Psychiatry 2005;76:833-8.

53. Kishima H, Saitoh Y, Osaki Y, Nishimura H, Kato A, Hatazawa J, et al. Motor cortex stimulation in patients with deafferentation pain: Activation of the posterior insula and thalamus. J Neurosci 2007;107:43-8.

54. Lazorthes Y, Sol JC, Fouso S, Roux FE, Verdié JC. Motor cortex stimulation for neuropathic pain. Acta Neurochir Suppl 2007;97(Pt 2):37-44.

55. Lefaucheur JP. The use of repetitive transcranial magnetic stimulation (rTMS) in chronic neuropathic pain. Neurophysiol Clin 2006;36:117-24.

56. Lefaucheur JP. de Andrade DC. Intraoperative neurophysiologic mapping of the central cortical region for epidural electrode placement in the treatment of neuropathic pain by motor cortex stimulation. Brain Stimul 2009;2:138-48.

57. Lefaucheur JP, Drouot X, Cunin P, Brucker R, Lepetit H, Créange A, et al. Motor cortex stimulation for the treatment of refractory peripheral neuropathic pain. Brain 2009;132:1463-71.

58. Lefaucheur JP, Drouot X, Ménard-Lefaucheur I, Keravel Y, Nguyen JP. Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain. Neurology 2006;67:1568-74.

59. Lefaucheur JP, Drouot X, Ménard-Lefaucheur I, Keravel Y, Nguyen JP. Motor cortex rTMS in chronic neuropathic pain: Relief associated with therosensory perception improvement. J Neurol Neurosurg Psychiatry 2008;79:1044-49.

60. Lefaucheur JP, Drouot X, Ménard-Lefaucheur I, Nguyen JP. Neuropathic pain controlled for more than a year by monthly sessions of repetitive transcranial magnetic stimulation of the motor cortex. Neurophysiol Clin 2004;34:91-5.

61. Lefaucheur JP, Hatem S, Nineb A, Ménard-Lefaucheur I, Wendling S, Keravel Y, et al. Somatotopic organization of the analgesic effects of motor cortex rTMS in neuropathic pain. Neurology 2006;67:1998-2004.

62. Lefaucheur JP, Holshheimer J, Goujon C, Keravel Y, Nguyen JP. Descending volley generated by efficacious epidural motor cortex stimulation in patients with chronic neuropathic pain. Exp Neurol 2010;222:609-14.

63. Lefaucheur JP, Keravel Y, Nguyen JP. Treatment of poststroke pain by epidural motor cortex stimulation with a new octopolar lead. Neurosurgery 2005;56:833-8.

64. Lefaucheur JP, Ménard-Lefaucheur I, Goujon C, Keravel Y, Nguyen JP. Predictive value of rTMS in the identification of responders to epidural motor cortex stimulation therapy for pain. J Pain 2011;10:1102-11.

65. Levy R, Deer TR, Henderson J. Intracranial neurostimulation for pain control: A review. Pain Physician 2010;13:157-65.

66. Lima MC, Fregni F. Motor cortex stimulation for chronic pain: Systematic review and meta-analysis of the literature. Neurology 2008;70:2329-37.

67. Maazawi J, Peyron R, Mertens P, Costes N, Magnin S, Sindou M, et al. Motor cortex stimulation for pain control induces changes in the endogenous opioid system. Neurology 2007;69:827-34.

68. Machado A, Azmi H, Rezaei AR. Motor cortex stimulation for refractory benign pain. Clin Neurophysiol 2007;54:70-7.
90. Rainov NG, Fels C, Heidecke V, Burkert W. Epidural electrical stimulation of the motor cortex in patients with facial neuralgia. Clin Neurol Neurosurg 1997;99:205-9.

91. Rainov NG, Heidecke V. Motor cortex stimulation for neuropathic facial pain. Neurol Res 2003;25:157-61.

92. Rasche D, Rinaldi PC, Young RF, Tonnier VM. Deep brain stimulation for treatment of various chronic pain syndromes. Neurosurg Focus 2006;21:E8

93. Laslan AM, Nasser M, Bahgat DA, Abdu E, Burchiel KJ. Motor cortex stimulation for long-term relief of chronic neuropathic pain: A 10-year experience. Pain 2006;121:43-52.

94. Roux FE, Ibarrola D, Lazortxes Y, Berry I. Chronic motor cortex stimulation for Phantom limb pain: A functional magnetic resonance imaging study: Technical case report. Neurosurgery 2001;48:681-7; discussion 687-8.

95. Saitoh Y, Hirano S, Akiyama H, Inose M, Hirata M, Yamamoto K, et al. Motor cortex stimulation to treat deafferentation pain. Acta Neurochir Suppl 2006;99:57-9.

96. Saitoh Y, Kato A, Ninomiya H, Baba T, Shibata M, Moshino T, et al. Primary motor cortex stimulation within the central sulcus for treating deafferentation pain. Acta Neurochir Suppl 2003;87:149-52.

97. Saitoh Y, Shibata M, Hirata M, Moshino T, Yoshimine T. Motor cortex stimulation for central and peripheral deafferentation pain: Report of eight cases. J Neurosurgery 2000;92:150-5.

98. Saitoh Y, Shibata M, Tanaka Y, Moshino T. Motor cortex stimulation of Phantom limb pain. Lancet 1999;353:212.

99. Sharan RD, Rosenow JM, Turbay M, Testerman R, Rezai AR. Precerebral stimulation for chronic pain. Neurosurg Clin N Am 2003;14:437-44.

100. Slavin KV, Nersesyan H, Colpan ME, Munawar N. Current algorithm for the surgical treatment of facial pain. Head Face Med 2007;3:30.

101. Smith H, Joint C, Schlugman D, Nandi D, Stein JF, Aziz T. Motor cortex stimulation for neuropathic pain. Neurosurg Focus 2001;1:1:E2.

102. Sokal P, Harat M, Paczkowski D, Rudai M, Birski M, Litwinowicz A. Results of Neurumodulation for the treatment of chronic pain. Neurol Neurochir Pol 2011;45:445-51.

103. Sol JC, Casaux J, Roux FE, Lotterie JA, Bousquet P, Verdié JC, et al. Chronic motor cortex stimulation for phantom limb pain: Correlations between relief and functional imaging studies. Stereotact Funct Neurosurg 2001;77:172-6.

104. Son BC, Lee SW, Choi ES, Sung JH, Hong JT. Motor cortex stimulation for central pain following a traumatic brain injury. Pain 2006;123:210-6.

105. Son BC, Lee SW, Choi ES, Sung JH, Hong JT. Motor cortex stimulation in a patient with intractable complex regional pain syndrome type II with hemibody involvement. J Neurosurg 2003;98:175-9.

106. Stadler JA 3rd, Ellens DJ, Rosenow JM. Deep brain stimulation and motor cortical stimulation for neuropathic pain. Curr Pain Headache Rep 2011;15:8-13.

107. Stidd DA, Wuolett A, Bowden K, Price T, Patwardhan A, Barker S, et al. Peripheral nerve stimulation for trigeminal neuropathic pain. Pain Physician 2012;15:27-33.

108. Tani N, Saitoh Y, Hirata M, Kato A, Yoshimine T, Bilateral cortical stimulation for deafferentation pain after spinal cord injury. J Neurosurg 2004;101:687-9.

109. Tarapore PE, Tate MC, Findlay AM, Horsma SM, Miziriz D, Berger MS, et al. Preoperative multimodal motor mapping: A comparison of magnetoencephalography imaging, navigated transcranial magnetic stimulation, and direct cortical stimulation. J Neurosurg 2012;117:354-62.

110. Thomas L, Bledsoe JM, Stead M, Sandroni P, Gorman D, Lee KH. Motor cortex and deep brain stimulation for the treatment of intractable neuropathic face pain. Curr Neurol Neurosci Rep 2009;9:120-6.

111. Tanei T, Kajita Y, Noda H, Takebayashi S, Nakatsubo D, Masawa S, et al. Efficacy of motor cortex stimulation for intractable central neuropathic pain: Comparison of stimulation parameters between post-stroke pain and other central pain. Neurol Med Chir (Tokyo) 2011;51:8-14.

112. Tanei T, Kajita Y, Wakabayashi T. Motor cortex stimulation for intractable neuropathic facial pain related to multiple sclerosis. Neurol Med Chir (Tokyo) 2010;50:604-7.

113. Tirakotai W, Riegel T, Sure U, Rohlfis J, Gharabaghi A, Bertalanffy H, et al. Image-guided motor cortex stimulation in patients with central pain. Minim Invasive Neurosurg 2004;47:273-7.

114. Tomaso B, Buadi R, Mondani M, Skrap M, Rumiati RI. Mental rotation in a patient with an implanted electrode grid in the motor cortex. Neuroreport 2005;16:1795-800.

115. Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation for the treatment of central pain. Acta Neurochir Suppl 1991;52:137-9.

116. Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Treatment of thalamic pain by chronic motor cortex stimulation. Pacing Clin Electrophysiol 1991;14:131-4.

117. Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation in patients with thalamic pain. J Neurosurg 1993;78:393-401.

118. Velasco F, Arregués C, Carrillo-Ruiz JD, Castro S, Velasco AL, Jiménez F, et al. Chronic motor cortex electrical stimulation applied to patients with complex regional pain syndrome. Pain 2009;147:91-8.

119. Yamamoto T, Katayama Y, Hirayama T, Tsubokawa T. Pharmacological classification of central post-stroke pain: Comparison with the results of Chronic motor cortex stimulation therapy. Pain 1997;72:5-12.

120. Yamamoto T, Katayama Y, Obuchi T, Kano T, Kiyosaki K, Oshima H, et al. Recording of corticospinal evoked potential for optimum placement of motor cortex stimulation electrodes in the treatment of post-stroke pain: Two case reports. Neurol Med Chir (Tokyo) 2007;47:409-14.

121. Zaghi S, Heine N, Fregni F. Brain stimulation for the treatment of pain: A review of costs, clinical effects, and mechanisms of treatment for three different central neuromodulatory approaches. J Pain Manag 2009;2:339-52.

122. Zakrewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother 2010;11:1239-54.